Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRICREST: Triamcinolone in CRPC
NCT07161778Phase 2Completed
- Sponsor
- Barts Health NHS Trust
- Start
- Oct 2011
- Primary completion
- Sep 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of triamcinolone in castration-resistant prostate cancer (CRPC), sponsored by Barts Health NHS Trust. Started Oct 2011; status: completed.
02
Drugs
triamcinolone
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07161778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07161778.